1.43 (1.07 to 1.90)) associated with lower graft-versus-host disease-free and relapse-free survival (GRFS) (Adjusted HR 1.20 (1.02 to 1.42)). Conversely, we observed no differences in terms of chronic GVHD, nonrelapse mortality, relapse and overall survival. However, we believe that patients stand to benefit from DRB3/4/5 loci being considered for unrelated donor selection to improve GRFS and then quality of life after unrelated HCT.
| I N T R O D U C T I O N
Allogeneic hematopoietic cell transplantation (HCT) is a widely used therapeutic option for most patients with life-threatening hematological disorders. In the absence of a matched sibling donor, the preferred source of stem cells is still a matched unrelated donor (MUD). Mismatching at HLA-A, -B, -C, -DRB1 loci has been repeatedly associated with higher risks of mortality when compared with HLA 8/8 MUD. [1] [2] [3] [4] [5] Allelic matching at these loci is now considered to be the gold standard for unrelated HCT. In Europe, patients are also matched at the HLA-DQB1 loci (10/10 match), though without any clear evidence yet of improved overall survival (OS). Currently, matches at the polymorphic DPB1 and DRB3/4/5 loci are not routinely considered for MUD selection. However, there is increasing evidence that matching at these loci may play a role in lowering transplant-related mortality (TRM) and/or the incidence of acute graft-versus-host disease (aGVHD). [5] [6] [7] [8] [9] DPB1 mismatching has previously been associated with higher risks of aGVHD and TRM but also with lower risks of relapse after HCT, resulting in no difference in OS. 5, 6, 10, 11 Matching status at DPB1 has been longly thought to tip toward either a lower risk of relapse or a lower risk of aGVHD.
Although DPB1 mismatching has been widely studied, very few is known about DRB3/4/5 mismatching. However, an outstanding study from van Balen and colleagues showed that a donor/recipient mismatched DRB3 molecule may induce a CD41 T-cell allo-immune response in the 10/10 MUD setting. 12 In this study, immune response directed against the mismatched DRB3 molecule was stronger than the one directed against mismatched HLA-DPB1 molecule. These results suggest that the impact of mismatching at DRB3/4/5 loci may have been until now underrated.
The impact of DRB3/4/5 mismatches was recently examined in a large retrospective cohort of patients. No association was found with OS, disease-free survival, relapse, grade III-IV aGVHD and TRM in patients matched for HLA-A, -B, -C, and -DRB1 loci (8/8 match). However, the cumulative adverse effect of HLA-DRB3/4/5 loci mismatches with HLA-DQB1 and -DPB1 mismatches led to poorer OS in cases involving 7/8 MUDs. 8 Lately, in a retrospective multicenter study, we identified DRB4 mismatches to be associated with higher TRM, aGVHD and lower OS in 10/10 MUD HCT. 9 The main limitation of this study was that all DRB4 mismatches were associated with at least one DPB1 mismatch. The effect of DRB4 mismatches could not therefore be analyzed separately from DPB1 mismatches.
We consequently decided to investigate the impact of DRB3/4/5 mismatches in a large retrospective multi-center cohort of French patients to be able to assess the specific role of DRB3/4/5 mismatches, independently from DPB1 mismatches if ever possible. We chose OS as our main clinical endpoint together with GVHD-free, relapse-free survival (GRFS), since it provides a better reflection of the real benefits that patients derive from HCT. Figure S1 ). 
| HCT outcome analysis
Clinical data were obtained through ProMISe (Project Manager Internet Server), a European internet-based system used by all French transplantation centers. Median follow-up was 58 months (interquartile range, 42 to 83; maximum 182). The primary endpoints for the analysis were overall survival (OS) and GVHD-free and relapse-free survival (GRFS) defined as absence of grade III-IV acute GVHD (aGVHD), systemic immunosuppressive therapy requiring chronic GVHD (cGVHD), relapse, or death. 13 Acute GVHD, cGVHD, relapse and nonrelapse mortality (NRM) were also examined.
| Statistical methods
All time-to-event outcomes were counted from the date of transplant to the date of event or date of last follow-up, except aGVHD, which was arbitrarily censored at four months. Kaplan-Meier estimator of the survival function was used to estimate OS and GRFS. The cumulative incidence of aGVHD, extensive cGVHD, NRM and relapse was also estimated. Factors associated with time-to-event outcomes were analyzed using multivariable Cox proportional hazards models (OS, GRFS) and cause-specific proportional hazard models in a competing risks framework (cGVHD, NRM and relapse). Acute GVHD was analyzed as a binary outcome given the absence of censoring, by using multivariable logistic regression models, which do not rely on any proportional 
| Mismatching at HLA-DRB3/4/5 and outcomes after HCT
The association between HLA-DRB3/4/5 mismatches and outcomes was analyzed comparing both DRB3/4/5 matched and mismatched groups. Outcomes at different timepoints are presented in Table 2 and 
| Adjusted analysis of outcomes after HCT
Multivariate analysis of outcomes is presented in Table 3 . This adjusted analysis confirms that DRB3/4/5 mismatches were significantly associated with higher risk of grade II-IV aGVHD (Adjusted OR 1.43, 95% CI GVHD, acute GVHD; cGVHD, chronic GVHD; GVHD, Graft-versus-host disease; GRFS, GVHD-free, relapse-free survival; mo, months; No., number of. One of the novelties of our investigation was to use GVHD-free, relapse-free survival (GRFS) as one of our main clinical endpoint, since it provides a better reflection of the real benefits that patients derive from HCT. 13 GRFS represents ideal recovery after HCT, without continuing morbidity, and also provides more information regarding HCT complications than the measurement of OS or disease-free survival alone. In other words, this endpoint reflects survival without significant ongoing morbidity, which is currently the major objective following HCT. We did indeed find that DRB3/4/5 mismatching has a substantial impact on GRFS which would certainly seem to reflect changes in quality of life after HCT.
A cumulative effect of DRB3/4/5 and DPB1 mismatches on OS had already been identified in HLA-A, -B, -C, -DRB1 7/8 matches but not in 8/8 matches. 8 Our study differs from this previous investigation for various reasons. Our cohort was based on 10/10 matched pairs and primary endpoints of our analysis were OS and GRFS, whereas Fernan- We did not observe any significant association of DRB3/4/5 mismatching and double mismatched DPB1 (HR 1.13, 95% CI 1.00 to 1.26).
Our work has strengths and limitations. Our study is limited by its retrospective setting and the lack of questionnaire information con- patients waiting for unrelated allo-HCT have a high probability of finding five or more matched donors. 16 Even though we did not identify any significant impact of DRB3/4/5 mismatches on OS, these patients stand to benefit from DRB3/4/5 loci being considered for unrelated donor selection to improve GRFS and then quality of life after unrelated HCT.
